Tel: 866-662-2852
In 2018, a federal jury found that Boehringer Ingelheim Pharmaceuticals Inc. was not forthright about the risk of potential bleeding injuries with its drug, Pradaxa (Dabigatran), and the jury awarded the plaintiff $250,000 for medical expenses and pain and suffering, as well as $1 million in punitive damages. This was the first trial win for plaintiffs, after the manufacturer had succeeded at three prior trials.
